Mar 6, 2009 by Brian Orelli, PhDDon't Let It Go!Sticking with a side business doesn't seem like such a bad idea in this market.
Mar 6, 2009 by Brian Orelli, PhDFor Drug Companies, R&D Is Spelled C-R-OOutsourcing, health-care style.
Mar 5, 2009 by Brian Orelli, PhD5 Stocks to Benefit From China's Health-Care PlanSame idea, different country.
Mar 4, 2009 by Brian Orelli, PhDVertex Combines to Keep From Being Ground UpIn a pinch, acquisitions are better than getting passed by.
Mar 3, 2009 by Brian Orelli, PhDA Tale of 2 WeeksTwo nasty notes from the FDA follow two approvals for Genzyme.
Mar 3, 2009 by Brian Orelli, PhDStop Worrying About Follow-On BiologicsThey're inevitable, but they won't hurt biotech as much as you might think.
Mar 2, 2009 by Brian Orelli, PhDPharma's Public Relations Bonus: Executive PayBonuses? We don't need no stinkin’ bonuses.
Feb 27, 2009 by Brian Orelli, PhDHooray for Stalemates!Government deadlock will likely bring more genetically engineered seeds to the EU.
Feb 27, 2009 by Brian Orelli, PhDWhen Will Someone Buy Natus Medical?This BABY is sporting much lower multiples.
Feb 27, 2009 by Brian Orelli, PhDCan $634 Billion Save the U.S. Health Care System?The down payment is going to be costly for many companies.
Feb 27, 2009 by Brian Orelli, PhDDouble Approvals, Accelerated GrowthGenzyme gets a pair of approvals.
Feb 26, 2009 by Brian Orelli, PhDObama's Uncertainty Is Unhealthy for InvestorsLots of talk, but investors are still in a wait-and-see mode.
Feb 26, 2009 by Brian Orelli, PhDRanbaxy Spoils It for EveryoneDrug companies suffer from guilt by association.
Feb 26, 2009 by Brian Orelli, PhDBig Blue Struts Its Stimulus StuffEveryone's grabbing a piece of the pie, IBM included.
